Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rousselot has presented two new in vivo experiments that were aimed at defining the action of Peptan Hydrolyzed Collagen on bone health, at the IOF World Congress on Osteoporosis.
Subscribe to our email newsletter
Rousselot said that previous in-vivo and in-vitro studies carried out with Peptan Hydrolysed Collagen and published in the March 2010 issue of ‘Bone’ have demonstrated the positive effect of this ingredient on bone cells (osteoblasts) and on bone matrix.
Rousselot claimed that these studies were performed on ovariectomised mice, which are a good model for post-menopause osteoporosis. The mice received a daily intake of Peptan during up to 24 weeks. Bone mineral density (BMD), CTX bone resorption marker and biomechanical properties of the bones were then measured.
Reportedly, the results fully confirm the positive effect of a daily intake of Peptan Hydrolysed Collagen that had already been observed in previous studies. BMD is higher in mice receiving a Peptan-enriched diet than in the control group which did not receive Peptan. Likewise, the bone resorption marker CTX is lower and bone strength is greater when the mice are fed with Peptan.
Additionally, these studies have shown that Peptan has a preventive effect on bone loss when given to the mice pre- ovariectomy. Peptan has also demonstrated a similar effect to raloxifene, a pharmaceutical used for post-menopausal osteoporosis.
Rousselot said that during the Vitafoods trade show, Geneva, May 18-20, 2010, the company is expected to present detailed results of these studies and the other health benefits on skin and joints associated with Peptan Hydrolysed Collagen.